AMD

Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Ultra-widefield camera captures images from macula, far peripheryA recently released ultra-widefield fundus camera takes images in true color and captures high-resolution imagess rom the macula to the far periphery.
OCTA system offers exquisite views
OCTA system offers exquisite viewsA new high-density OCT angiography system (AngioVueHD, OptoVue) provides exquisite views of the retinal microvasculature without the need for injection of fluorescein dye.
IOL selection important in patients with retinal diseaseWhen dealing with patients with retinal disease, macular disease, or a meaningful risk of retinal detachment, certain types of IOLs should be avoided due to potential complications.
Real-world outcomes with aflibercept better in treatment-naïve patientsAfter 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapyAfter 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Anti-PDGF inhibitor development continues despite negative resultsDespite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
DARPin molecule prolongs anti-VEGF activity in nAMDA phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
No one imaging tool fits all in identifying AMD lesionsMultimodal imaging, including traditional and newer techniques, is necessary for identifying the spectrum of retinal lesions associated with age-related macular degeneration (AMD), said David Sarraf, MD.
var script= ' ';